Related Experiment Video
Updated: Jan 6, 2026

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
Serum Interleukin-8 Levels Identify Non-Atrial Fibrillation Patients at Risk for Catheterization-Confirmed Diastolic
Zhiyuan Ma1,2, Zhiqiang Yang1, Xiaotong Ji1
1Heart Center, The First Hospital of Hebei Medical University, Hebei Medical University, 89 Donggang Road, Shijiazhuang, 050031, Hebei Province, China.
Insights
Serum interleukin-8 (IL-8) shows promise as an early biomarker for left ventricular diastolic dysfunction (LVDD), a key factor in heart failure with preserved ejection fraction (HFpEF). Combining IL-8 with other markers improves diagnostic accuracy for timely intervention.
Area of Science:
- Cardiology
- Biomarker Discovery
- Inflammation Research
Background:
- Left ventricular diastolic dysfunction (LVDD) is crucial for diagnosing heart failure with preserved ejection fraction (HFpEF).
- Current noninvasive methods may miss early LVDD, delaying treatment.
- Interleukin-8 (IL-8) is implicated in inflammation and cardiovascular remodeling, suggesting its potential as an early diagnostic marker.
Purpose of the Study:
- To investigate serum IL-8 as a potential noninvasive biomarker for early detection of catheterization-confirmed LVDD.
- To evaluate the diagnostic performance of IL-8, alone and in combination with established markers, for LVDD.
Main Methods:
- Retrospective cohort study (n=1,014) assessing 12 inflammatory cytokines using flow cytometry.
- Prospective validation cohort (n=248) to confirm IL-8 findings.
- Analysis of diagnostic performance using receiver operating characteristic curves (AUC).
Main Results:
- Serum IL-8 levels were significantly elevated in LVDD patients without atrial fibrillation (2.26-fold increase).
- IL-8 was independently associated with LVDD in the discovery cohort (adjusted OR: 13.2).
- Combining IL-8 with B-type natriuretic peptide (BNP) and E/e' ratio improved diagnostic accuracy (AUC: 0.79).
Conclusions:
- Serum IL-8 is an independent biomarker for diagnosing catheterization-confirmed LVDD in patients without atrial fibrillation.
- IL-8 enhances diagnostic performance when combined with traditional markers like BNP and E/e'.
- IL-8 offers a promising tool for early HFpEF identification and risk stratification, aiding in unexplained dyspnea evaluation.
Abstract:
Left ventricular diastolic dysfunction (LVDD), confirmed by left heart catheterization, is the gold standard for diagnosing heart failure with preserved ejection fraction (HFpEF). However, current noninvasive diagnostic tools may fail to detect early-stage LVDD in patients without prior hospitalization for heart failure, delaying timely intervention. Given its role in inflammation and cardiovascular remodeling, serum interleukin-8 (IL-8) may serve as a potential biomarker for early detection. We conducted a retrospective cohort study that included patients who underwent diagnostic left heart catheterization between March 2020 and August 2024. In the discovery cohort (n = 1,014), we assessed the associations of 12 inflammatory cytokines with catheterization-confirmed LVDD via a highly sensitive flow cytometer. IL-8, the most strongly associated cytokine, was further evaluated in a separate prospective validation cohort (n = 248). Diagnostic performance was evaluated via the area under the receiver operating characteristic curve (AUC). IL-8 levels were significantly elevated in LVDD patients without atrial fibrillation compared with controls, with a 2.26-fold median increase (P < 0.001). In the discovery cohort (n = 1,014), IL-8 was independently associated with LVDD (adjusted odds ratio for highest vs. lowest quartile: 13.2 [95% CI: 6.5-26.7]). These findings were validated in an independent cohort. Combining IL-8 with B-type natriuretic peptide (BNP) and the E/e' ratio improved diagnostic accuracy, achieving an AUC of 0.79 (95% CI: 0.74-0.85). Serum IL-8 is an independent biomarker for diagnosing catheterization-confirmed LVDD in patients without atrial fibrillation. Its combination with traditional markers enhances diagnostic performance, offering a promising tool for early identification and potential risk stratification of HFpEF. Clinically, IL-8 testing may help identify patients with unexplained dyspnea who warrant closer monitoring or earlier therapeutic intervention.
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Dysrhythmias V: Evaluating Dysrhythmias

